Key result
K 4423, isoproterenol, papaverine, and methamidoline inhibit ADP- and noradrenaline-induced platelet aggregation.
Why the study?
The in vitro effects of several cardiovascular and other agents on human platelet aggregation were not fully characterized.
Do K 4423, isoproterenol, phentolamine, papaverine, and methamidoline affect human platelet aggregation in vitro?
Population
Human platelets studied in vitro
Comparison
K 4423, isoproterenol, phentolamine, papaverine, methamidoline vs control
Design
In vitro experimental study
Authors
Loading...
Should not yet inform practice; hypothesis-generating for in vivo antithrombotic effects.
Do K 4423, isoproterenol, phentolamine, papaverine, and methamidoline affect human platelet aggregation in vitro?
In vitro testing demonstrates that several cardiovascular drugs, including isoproterenol and papaverine, inhibit ADP- or noradrenaline-induced human platelet aggregation.
Sacchetti et al. (1973) studied Platelet aggregation. Cardiovascular drugs (K 4423, isoproterenol, phentolamine, papaverine, methamidoline) was evaluated on Platelet aggregation induced by ADP or noradrenaline. In vitro testing showed that K 4423, isoproterenol, papaverine, and methamidoline inhibited ADP- and noradrenaline-induced platelet aggregation, while phentolamine only inhibited the latter.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: